BR9810911A - Composto, e, processo para tratar câncer em um mamìfero - Google Patents
Composto, e, processo para tratar câncer em um mamìferoInfo
- Publication number
- BR9810911A BR9810911A BR9810911-1A BR9810911A BR9810911A BR 9810911 A BR9810911 A BR 9810911A BR 9810911 A BR9810911 A BR 9810911A BR 9810911 A BR9810911 A BR 9810911A
- Authority
- BR
- Brazil
- Prior art keywords
- group
- mammal
- compound
- treat cancer
- formula
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- -1 N-substituted amino Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 239000003966 growth inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000003544 oxime group Chemical group 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005309 thioalkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTO, E, PROCESSO PARA TRATAR CâNCER EM UM MAMìFERO". OS compostos da presente invenção incluem inibidores de crescimento de célula que são peptídeos de fórmula (I) - A - B - D - E - F - (G)~ r~- (K)~ s~ e sais de ácido dos mesmos, em que A, B, D, F, G, e K são resíduos de <244>-aminoácido, e s e r são, cada, independentemente, 0 ou 1. L é um radical monovalente, como por exemplo, um grupo amino, um grupo amino N-substituído, um grupo ß-hidroxilamino, um grupo hidrazido, um grupo alcóxi, um grupo tioalcóxi, um grupo aminóxi, ou um grupo oximato. A presente invenção também inclui um processo para o tratamento de câncer em um mamífero, como humano, compreendendo a administração ao mamífero de uma quantidade efetiva de um composto de fórmula (I) em uma composição farmaceuticamente aceitável.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/896,394 US6143721A (en) | 1997-07-18 | 1997-07-18 | Dolastatin 15 derivatives |
PCT/US1998/013901 WO1999003879A1 (en) | 1997-07-18 | 1998-07-07 | Dolastatin 15 derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9810911A true BR9810911A (pt) | 2000-08-01 |
Family
ID=25406130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9810911-1A BR9810911A (pt) | 1997-07-18 | 1998-07-07 | Composto, e, processo para tratar câncer em um mamìfero |
Country Status (33)
Country | Link |
---|---|
US (6) | US6143721A (pt) |
EP (1) | EP0991658B1 (pt) |
JP (4) | JP4508413B2 (pt) |
KR (1) | KR100579748B1 (pt) |
CN (1) | CN1268636C (pt) |
AR (1) | AR018501A1 (pt) |
AT (1) | ATE314387T1 (pt) |
AU (1) | AU750120B2 (pt) |
BG (1) | BG65212B1 (pt) |
BR (1) | BR9810911A (pt) |
CA (1) | CA2296036C (pt) |
CO (1) | CO4990967A1 (pt) |
CY (1) | CY1107047T1 (pt) |
CZ (1) | CZ303045B6 (pt) |
DE (1) | DE69832982T2 (pt) |
DK (1) | DK0991658T3 (pt) |
ES (1) | ES2258819T3 (pt) |
HK (1) | HK1029125A1 (pt) |
HR (1) | HRP980397A2 (pt) |
HU (1) | HU228996B1 (pt) |
ID (1) | ID24669A (pt) |
IL (1) | IL133784A (pt) |
MY (1) | MY135057A (pt) |
NO (1) | NO326827B1 (pt) |
NZ (1) | NZ502296A (pt) |
PL (1) | PL197884B1 (pt) |
PT (1) | PT991658E (pt) |
RU (1) | RU2195462C2 (pt) |
SK (1) | SK286581B6 (pt) |
TR (2) | TR200103545T2 (pt) |
TW (1) | TW533217B (pt) |
WO (1) | WO1999003879A1 (pt) |
ZA (1) | ZA986358B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010009901A1 (en) * | 1996-12-11 | 2001-07-26 | Basf Aktiengesellschaft Germany | Antineoplastic peptides |
US6143721A (en) * | 1997-07-18 | 2000-11-07 | Basf Aktiengesellschaft | Dolastatin 15 derivatives |
WO2001058928A1 (en) * | 2000-02-08 | 2001-08-16 | Nagasawa Herbert T | N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents |
US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) * | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7064211B2 (en) * | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
PL219737B1 (pl) | 2002-03-22 | 2015-07-31 | Eisai R & D Man Co | Pochodne hemiasterliny, środek farmaceutyczny i zastosowanie pochodnych i zastosowanie hemiasterliny |
DK1545613T3 (da) * | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
US20060148014A1 (en) * | 2004-12-09 | 2006-07-06 | Sergei Agoulnik | Tubulin isotype screening in cancer therapy using hemiasterlin analogs |
CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics Inc | composto de ligação de domìnio bir da iap |
CN111499748A (zh) | 2007-07-16 | 2020-08-07 | 健泰科生物技术公司 | 抗cd79b抗体和免疫偶联物及使用方法 |
PE20090481A1 (es) | 2007-07-16 | 2009-05-18 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso |
DE102007039706A1 (de) | 2007-08-22 | 2009-02-26 | Erhard Prof. Dr.-Ing. Kohn | Chemischer Sensor auf Diamantschichten |
EP3269737B1 (en) | 2008-01-31 | 2024-06-19 | Genentech, Inc. | Anti-cd79b antibodies and immunoconjugates and methods of use |
CA2784748A1 (en) * | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
AR080154A1 (es) | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos cd20 y su utilizacion |
SG182724A1 (en) | 2010-02-12 | 2012-08-30 | Pharmascience Inc | Iap bir domain binding compounds |
US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
CN114262344A (zh) | 2014-02-28 | 2022-04-01 | 杭州多禧生物科技有限公司 | 带电荷链接体及其在共轭反应上的应用 |
CA3069221C (en) | 2014-09-23 | 2023-04-04 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
KR20220150408A (ko) | 2016-11-14 | 2022-11-10 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
JPWO2023033129A1 (pt) | 2021-09-03 | 2023-03-09 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816444A (en) * | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US4879278A (en) * | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
SG87056A1 (en) * | 1991-08-09 | 2002-03-19 | Teikoku Hormone Mfg Co Ltd | Novel tetrapeptide derivative |
US5533097A (en) * | 1992-02-26 | 1996-07-02 | Motorola, Inc. | Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available |
US5448045A (en) * | 1992-02-26 | 1995-09-05 | Clark; Paul C. | System for protecting computers via intelligent tokens or smart cards |
US5831002A (en) * | 1992-05-20 | 1998-11-03 | Basf Aktiengesellschaft | Antitumor peptides |
IL105651A (en) * | 1992-05-20 | 1998-07-15 | Basf Ag | History of dolastatin preparation and pharmaceutical preparations containing them |
ATE196296T1 (de) * | 1992-12-16 | 2000-09-15 | Basf Ag | Dolastatin analog |
US5554993A (en) * | 1994-01-04 | 1996-09-10 | Panasonic Technologies, Inc. | Global position determining system and method |
US5504191A (en) * | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5530097A (en) * | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5554725A (en) * | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5663149A (en) * | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5618232A (en) * | 1995-03-23 | 1997-04-08 | Martin; John R. | Dual mode gaming device methods and systems |
US5970143A (en) * | 1995-11-22 | 1999-10-19 | Walker Asset Management Lp | Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols |
US5807984A (en) * | 1995-11-09 | 1998-09-15 | Basf Aktienegesellschaft | Oligopeptides, the preparation and use thereof |
TW474946B (en) * | 1995-12-15 | 2002-02-01 | Basf Ag | Novel compounds, the preparation and use thereof |
CA2287379C (en) * | 1997-01-10 | 2005-10-04 | Silicon Gaming-Nevada | Method and apparatus for providing authenticated, secure on-line communication between remote locations |
US6143721A (en) * | 1997-07-18 | 2000-11-07 | Basf Aktiengesellschaft | Dolastatin 15 derivatives |
US6554705B1 (en) * | 1997-08-22 | 2003-04-29 | Blake Cumbers | Passive biometric customer identification and tracking system |
US6629591B1 (en) * | 2001-01-12 | 2003-10-07 | Igt | Smart token |
US6438382B1 (en) * | 2001-02-14 | 2002-08-20 | Telefonaktiebolaget Lm Ericsson (Publ.) | Expedited location determination in analog service areas |
-
1997
- 1997-07-18 US US08/896,394 patent/US6143721A/en not_active Expired - Lifetime
-
1998
- 1998-07-07 CN CNB988073595A patent/CN1268636C/zh not_active Expired - Fee Related
- 1998-07-07 AU AU84758/98A patent/AU750120B2/en not_active Ceased
- 1998-07-07 CZ CZ20000176A patent/CZ303045B6/cs not_active IP Right Cessation
- 1998-07-07 EP EP98935531A patent/EP0991658B1/en not_active Expired - Lifetime
- 1998-07-07 AT AT98935531T patent/ATE314387T1/de active
- 1998-07-07 NZ NZ502296A patent/NZ502296A/en not_active IP Right Cessation
- 1998-07-07 TR TR2001/03545T patent/TR200103545T2/xx unknown
- 1998-07-07 ID IDW20000322A patent/ID24669A/id unknown
- 1998-07-07 RU RU2000103960/04A patent/RU2195462C2/ru not_active IP Right Cessation
- 1998-07-07 CA CA002296036A patent/CA2296036C/en not_active Expired - Fee Related
- 1998-07-07 SK SK1879-99A patent/SK286581B6/sk not_active IP Right Cessation
- 1998-07-07 JP JP2000503101A patent/JP4508413B2/ja not_active Expired - Fee Related
- 1998-07-07 WO PCT/US1998/013901 patent/WO1999003879A1/en active IP Right Grant
- 1998-07-07 KR KR1020007000565A patent/KR100579748B1/ko not_active IP Right Cessation
- 1998-07-07 HU HU0004234A patent/HU228996B1/hu not_active IP Right Cessation
- 1998-07-07 BR BR9810911-1A patent/BR9810911A/pt not_active Application Discontinuation
- 1998-07-07 ES ES98935531T patent/ES2258819T3/es not_active Expired - Lifetime
- 1998-07-07 DK DK98935531T patent/DK0991658T3/da active
- 1998-07-07 TR TR2000/00132T patent/TR200000132T2/xx unknown
- 1998-07-07 IL IL13378498A patent/IL133784A/xx not_active IP Right Cessation
- 1998-07-07 PT PT98935531T patent/PT991658E/pt unknown
- 1998-07-07 DE DE69832982T patent/DE69832982T2/de not_active Expired - Lifetime
- 1998-07-07 PL PL338144A patent/PL197884B1/pl unknown
- 1998-07-15 AR ARP980103445A patent/AR018501A1/es active IP Right Grant
- 1998-07-16 HR HR08/896,394A patent/HRP980397A2/hr not_active Application Discontinuation
- 1998-07-17 CO CO98040961A patent/CO4990967A1/es unknown
- 1998-07-17 ZA ZA9806358A patent/ZA986358B/xx unknown
- 1998-07-18 TW TW087111729A patent/TW533217B/zh active
- 1998-07-18 MY MYPI98003298A patent/MY135057A/en unknown
-
2000
- 2000-01-17 NO NO20000231A patent/NO326827B1/no not_active IP Right Cessation
- 2000-01-17 BG BG104089A patent/BG65212B1/bg unknown
- 2000-07-18 US US09/618,694 patent/US6458765B1/en not_active Expired - Lifetime
- 2000-12-28 HK HK00108461A patent/HK1029125A1/xx not_active IP Right Cessation
-
2002
- 2002-09-25 US US10/255,118 patent/US7084110B2/en not_active Expired - Lifetime
-
2006
- 2006-03-13 CY CY20061100348T patent/CY1107047T1/el unknown
- 2006-04-18 US US11/406,512 patent/US7662786B2/en not_active Expired - Fee Related
-
2008
- 2008-12-11 JP JP2008315263A patent/JP5122429B2/ja not_active Expired - Fee Related
- 2008-12-11 JP JP2008315269A patent/JP5047935B2/ja not_active Expired - Fee Related
-
2009
- 2009-12-29 US US12/648,446 patent/US8163698B2/en not_active Expired - Fee Related
-
2012
- 2012-04-16 US US13/447,529 patent/US20130046077A1/en not_active Abandoned
- 2012-06-20 JP JP2012138485A patent/JP2012211164A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9810911A (pt) | Composto, e, processo para tratar câncer em um mamìfero | |
BR9911932A (pt) | Composto | |
BR9713465A (pt) | Inibidores metalotprotease de amina cìclica sibstituìda | |
BR9808017A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratar o câncer em um mamìfero e para a fabricação de um medicamento para o tratamento do câncer | |
BR9813973A (pt) | Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição. | |
BR9609424A (pt) | Novos peptìdeos, compostos, composição farmacêutica, processo para tratar um tumor em um mamìfero, e, processo para preparar os compostos | |
BR9806870A (pt) | Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo. | |
BR9916732A (pt) | Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa) | |
BR0114576A (pt) | Composto, composição farmacêutica, uso de um composto, método de tratar um estado doentio e processo para preparar um composto | |
BRPI0514420A (pt) | peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo | |
BR9609006A (pt) | Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente. | |
BR0108694A (pt) | Derivados de ácido malÈnico, processo para preparação dos mesmos, uso dos mesmos como inibidor de atividade do fator xa e composições farmacêuticas que contêm os mesmos | |
BR9908275A (pt) | Inibidores de enzimas fosfolipase | |
BR9910849A (pt) | Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido. | |
BR9712202A (pt) | Composto, processo para preparar o mesmo, composicão farmacêutica, processo para o tratamento de inflamacão neurogênica em um indivíduo em necessidade deste tratamento, e, uso do composto. | |
BR0213139A (pt) | Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica | |
BR0211200A (pt) | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
ATE260658T1 (de) | Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen | |
BR0211118A (pt) | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal | |
BR0316629A (pt) | Uréias e carbamatos substituìdos | |
NZ326238A (en) | Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides | |
BR0109109A (pt) | Composto, uso do mesmo, processo para prepará-lo, composição farmacêutica, e, método de tratar um estado doentio mediado por ccr5 em mamìferos | |
BR9908125A (pt) | Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico | |
BR0215063A (pt) | Derivados de hidroxifenil-pirazol ativos como inibidores de cinase, processo para preparação dos mesmos e composições farmacêuticas compreendendo-os | |
DE69125216D1 (de) | Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Free format text: ABBOTT GMBH & CO. KG (DE) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 37, 8O 11, 13 DA LPI |
|
B15V | Prolongation of time limit allowed |
Free format text: DEVOLUCAO DE PRAZO CONCEDIDA - RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 15 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] |